Author(s): Jason R. Westin, M.D., Olalekan O. Oluwole, M.D., Marie José Kersten, M.D., Ph.D., David B. Miklos, M.D., Ph.D., Miguel-Angel Perales, M.D., Armin Ghobadi, M.D., Aaron P. Rapoport, M.D., Anna Sureda, M.D., Ph.D., Caron A. Jacobson, M.D., Umar Farooq, M.D., Tom van Meerten, M.D., Ph.D., Matthew Ulrickson, M.D., Mahmoud Elsawy, M.D., Lori A. Leslie, M.D., Sridhar Chaganti, M.D., Michael Dickinson, M.D., Kathleen Dorritie, M.D., Patrick M. Reagan, M.D., Joseph McGuirk, D.O., Kevin W. Song, M.D., Peter A. Riedell, M.D., Monique C. Minnema, M.D., Ph.D., Yin Yang, M.D., Saran Vardhanabhuti, Ph.D., Simone Filosto, Ph.D., Paul Cheng, M.D., Ph.D., Shilpa A. Shahani, M.D., Marco Schupp, M.D., Christina To, M.D., and Frederick L. Locke, M.D. for the ZUMA-7 Investigators and Kite Members*
Author AffiliationsFrom University of Texas M.D. Anderson Cancer Center, Houston (J.R.W.); Vanderbilt–Ingram Cancer Center, Nashville (O.O.O.); Amsterdam University Medical Center (UMC), University of Amsterdam, Cancer Center Amsterdam, Amsterdam (M.J.K.), UMC Groningen, Groningen (T.M.), and UMC Utrecht, Utrecht (M.C.M.) — all in the Netherlands; Stanford University School of Medicine, Stanford (D.B.M.), and Kite, Santa Monica (Y.Y., S.V., S.F., P.C., S.A.S., M.S., C.T.) — both in California; Memorial Sloan Kettering Cancer Center, New York (M.-A.P.), and University of Rochester School of Medicine, Rochester (P.M.R.) — both in New York; Washington University School of Medicine, St. Louis (A.G.); Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore (A.P.R.); Servei d’Hematologia Clínica, Institut Català d’Oncologia–Hospitalet, Institut de Recerca Biomèdica de Bellvitge, Universitat de Barcelona, Barcelona (A.S.B.); Dana–Farber Cancer Institute, Boston (C.A.J.); University of Iowa, Iowa City (U.F.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (M.U.); the Division of Hematology and Hematologic Oncology, Department of Medicine, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS (M.E.), and Vancouver General Hospital, BC Cancer, University of British Columbia, Vancouver (K.W.S.) — both in Canada; John Theurer Cancer Center, Hackensack, NJ (L.A.L.); the Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom (S.C.); Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and the University of Melbourne, Melbourne (M.D.); UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh (K.D.); University of Kansas Cancer Center, Kansas City (J.M.); David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (P.A.R.); and Moffitt Cancer Center, Tampa, FL (F.L.L.).